nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—SLC29A1—pancreatic cancer	0.478	1	CbGaD
Dipyridamole—SLC29A1—Gemcitabine—pancreatic cancer	0.0936	0.288	CbGbCtD
Dipyridamole—SLC29A1—Fluorouracil—pancreatic cancer	0.0801	0.246	CbGbCtD
Dipyridamole—ABCC5—Fluorouracil—pancreatic cancer	0.0612	0.188	CbGbCtD
Dipyridamole—ABCC4—Fluorouracil—pancreatic cancer	0.0294	0.0903	CbGbCtD
Dipyridamole—ABCC4—Sunitinib—pancreatic cancer	0.0223	0.0687	CbGbCtD
Dipyridamole—ABCB1—Tamoxifen—pancreatic cancer	0.00774	0.0238	CbGbCtD
Dipyridamole—ABCB1—Gemcitabine—pancreatic cancer	0.00667	0.0205	CbGbCtD
Dipyridamole—ABCB1—Erlotinib—pancreatic cancer	0.00658	0.0202	CbGbCtD
Dipyridamole—ABCB1—Irinotecan—pancreatic cancer	0.00594	0.0182	CbGbCtD
Dipyridamole—ABCB1—Docetaxel—pancreatic cancer	0.00435	0.0134	CbGbCtD
Dipyridamole—ABCB1—Sunitinib—pancreatic cancer	0.00433	0.0133	CbGbCtD
Dipyridamole—ABCB1—Doxorubicin—pancreatic cancer	0.00325	0.00997	CbGbCtD
Dipyridamole—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000104	0.00117	CcSEcCtD
Dipyridamole—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000104	0.00117	CcSEcCtD
Dipyridamole—Somnolence—Gemcitabine—pancreatic cancer	0.000104	0.00117	CcSEcCtD
Dipyridamole—Migraine—Doxorubicin—pancreatic cancer	0.000104	0.00116	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000104	0.00116	CcSEcCtD
Dipyridamole—Fatigue—Irinotecan—pancreatic cancer	0.000103	0.00116	CcSEcCtD
Dipyridamole—Paraesthesia—Fluorouracil—pancreatic cancer	0.000103	0.00116	CcSEcCtD
Dipyridamole—Alopecia—Docetaxel—pancreatic cancer	0.000103	0.00116	CcSEcCtD
Dipyridamole—Pruritus—Sunitinib—pancreatic cancer	0.000103	0.00116	CcSEcCtD
Dipyridamole—Pain—Irinotecan—pancreatic cancer	0.000103	0.00115	CcSEcCtD
Dipyridamole—Dyspnoea—Fluorouracil—pancreatic cancer	0.000102	0.00115	CcSEcCtD
Dipyridamole—Somnolence—Fluorouracil—pancreatic cancer	0.000102	0.00115	CcSEcCtD
Dipyridamole—Dyspepsia—Fluorouracil—pancreatic cancer	0.000101	0.00114	CcSEcCtD
Dipyridamole—Nausea—Tamoxifen—pancreatic cancer	0.000101	0.00113	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000101	0.00113	CcSEcCtD
Dipyridamole—Fatigue—Gemcitabine—pancreatic cancer	0.000101	0.00113	CcSEcCtD
Dipyridamole—Cardiac arrest—Doxorubicin—pancreatic cancer	0.0001	0.00112	CcSEcCtD
Dipyridamole—Pain—Gemcitabine—pancreatic cancer	9.99e-05	0.00112	CcSEcCtD
Dipyridamole—Nausea—Erlotinib—pancreatic cancer	9.99e-05	0.00112	CcSEcCtD
Dipyridamole—Diarrhoea—Sunitinib—pancreatic cancer	9.97e-05	0.00112	CcSEcCtD
Dipyridamole—Dysgeusia—Docetaxel—pancreatic cancer	9.95e-05	0.00112	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	9.92e-05	0.00111	CcSEcCtD
Dipyridamole—Feeling abnormal—Irinotecan—pancreatic cancer	9.89e-05	0.00111	CcSEcCtD
Dipyridamole—Dysphagia—Epirubicin—pancreatic cancer	9.84e-05	0.0011	CcSEcCtD
Dipyridamole—Back pain—Docetaxel—pancreatic cancer	9.83e-05	0.0011	CcSEcCtD
Dipyridamole—Pain—Fluorouracil—pancreatic cancer	9.83e-05	0.0011	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Irinotecan—pancreatic cancer	9.81e-05	0.0011	CcSEcCtD
Dipyridamole—Muscle spasms—Docetaxel—pancreatic cancer	9.77e-05	0.0011	CcSEcCtD
Dipyridamole—Dizziness—Sunitinib—pancreatic cancer	9.63e-05	0.00108	CcSEcCtD
Dipyridamole—Feeling abnormal—Gemcitabine—pancreatic cancer	9.63e-05	0.00108	CcSEcCtD
Dipyridamole—Abdominal pain upper—Doxorubicin—pancreatic cancer	9.62e-05	0.00108	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Doxorubicin—pancreatic cancer	9.62e-05	0.00108	CcSEcCtD
Dipyridamole—Angina pectoris—Epirubicin—pancreatic cancer	9.58e-05	0.00108	CcSEcCtD
Dipyridamole—Abdominal pain—Irinotecan—pancreatic cancer	9.48e-05	0.00107	CcSEcCtD
Dipyridamole—Feeling abnormal—Fluorouracil—pancreatic cancer	9.47e-05	0.00106	CcSEcCtD
Dipyridamole—Anaemia—Docetaxel—pancreatic cancer	9.39e-05	0.00105	CcSEcCtD
Dipyridamole—Vomiting—Sunitinib—pancreatic cancer	9.26e-05	0.00104	CcSEcCtD
Dipyridamole—Rash—Sunitinib—pancreatic cancer	9.18e-05	0.00103	CcSEcCtD
Dipyridamole—Dermatitis—Sunitinib—pancreatic cancer	9.18e-05	0.00103	CcSEcCtD
Dipyridamole—Urticaria—Fluorouracil—pancreatic cancer	9.13e-05	0.00103	CcSEcCtD
Dipyridamole—Headache—Sunitinib—pancreatic cancer	9.12e-05	0.00102	CcSEcCtD
Dipyridamole—Syncope—Docetaxel—pancreatic cancer	9.11e-05	0.00102	CcSEcCtD
Dipyridamole—Dysphagia—Doxorubicin—pancreatic cancer	9.1e-05	0.00102	CcSEcCtD
Dipyridamole—Palpitations—Docetaxel—pancreatic cancer	8.98e-05	0.00101	CcSEcCtD
Dipyridamole—Loss of consciousness—Docetaxel—pancreatic cancer	8.93e-05	0.001	CcSEcCtD
Dipyridamole—Cough—Docetaxel—pancreatic cancer	8.87e-05	0.000996	CcSEcCtD
Dipyridamole—Angina pectoris—Doxorubicin—pancreatic cancer	8.87e-05	0.000996	CcSEcCtD
Dipyridamole—Hypersensitivity—Irinotecan—pancreatic cancer	8.84e-05	0.000993	CcSEcCtD
Dipyridamole—Convulsion—Docetaxel—pancreatic cancer	8.8e-05	0.000989	CcSEcCtD
Dipyridamole—Hypertension—Docetaxel—pancreatic cancer	8.77e-05	0.000985	CcSEcCtD
Dipyridamole—Arthralgia—Docetaxel—pancreatic cancer	8.65e-05	0.000972	CcSEcCtD
Dipyridamole—Myalgia—Docetaxel—pancreatic cancer	8.65e-05	0.000972	CcSEcCtD
Dipyridamole—Chest pain—Docetaxel—pancreatic cancer	8.65e-05	0.000972	CcSEcCtD
Dipyridamole—Nausea—Sunitinib—pancreatic cancer	8.65e-05	0.000972	CcSEcCtD
Dipyridamole—Asthenia—Irinotecan—pancreatic cancer	8.61e-05	0.000967	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	8.59e-05	0.000965	CcSEcCtD
Dipyridamole—Hypersensitivity—Fluorouracil—pancreatic cancer	8.47e-05	0.000951	CcSEcCtD
Dipyridamole—Dry mouth—Docetaxel—pancreatic cancer	8.46e-05	0.00095	CcSEcCtD
Dipyridamole—Asthenia—Gemcitabine—pancreatic cancer	8.39e-05	0.000942	CcSEcCtD
Dipyridamole—Oedema—Docetaxel—pancreatic cancer	8.29e-05	0.000931	CcSEcCtD
Dipyridamole—Anaphylactic shock—Docetaxel—pancreatic cancer	8.29e-05	0.000931	CcSEcCtD
Dipyridamole—Pruritus—Gemcitabine—pancreatic cancer	8.27e-05	0.000929	CcSEcCtD
Dipyridamole—Diarrhoea—Irinotecan—pancreatic cancer	8.21e-05	0.000922	CcSEcCtD
Dipyridamole—Shock—Docetaxel—pancreatic cancer	8.16e-05	0.000916	CcSEcCtD
Dipyridamole—Nervous system disorder—Docetaxel—pancreatic cancer	8.13e-05	0.000913	CcSEcCtD
Dipyridamole—Pruritus—Fluorouracil—pancreatic cancer	8.13e-05	0.000913	CcSEcCtD
Dipyridamole—Thrombocytopenia—Docetaxel—pancreatic cancer	8.12e-05	0.000912	CcSEcCtD
Dipyridamole—Tachycardia—Docetaxel—pancreatic cancer	8.09e-05	0.000909	CcSEcCtD
Dipyridamole—Skin disorder—Docetaxel—pancreatic cancer	8.06e-05	0.000905	CcSEcCtD
Dipyridamole—Bradycardia—Epirubicin—pancreatic cancer	8.02e-05	0.0009	CcSEcCtD
Dipyridamole—Diarrhoea—Gemcitabine—pancreatic cancer	8e-05	0.000898	CcSEcCtD
Dipyridamole—Dizziness—Irinotecan—pancreatic cancer	7.93e-05	0.000891	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—pancreatic cancer	7.91e-05	0.000889	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—pancreatic cancer	7.89e-05	0.000886	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—pancreatic cancer	7.87e-05	0.000884	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—pancreatic cancer	7.87e-05	0.000884	CcSEcCtD
Dipyridamole—Diarrhoea—Fluorouracil—pancreatic cancer	7.86e-05	0.000883	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—pancreatic cancer	7.83e-05	0.00088	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—pancreatic cancer	7.81e-05	0.000878	CcSEcCtD
Dipyridamole—Hypotension—Docetaxel—pancreatic cancer	7.75e-05	0.00087	CcSEcCtD
Dipyridamole—Vomiting—Irinotecan—pancreatic cancer	7.63e-05	0.000857	CcSEcCtD
Dipyridamole—Dizziness—Fluorouracil—pancreatic cancer	7.6e-05	0.000853	CcSEcCtD
Dipyridamole—Rash—Irinotecan—pancreatic cancer	7.56e-05	0.00085	CcSEcCtD
Dipyridamole—Dermatitis—Irinotecan—pancreatic cancer	7.56e-05	0.000849	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	7.56e-05	0.000849	CcSEcCtD
Dipyridamole—Headache—Irinotecan—pancreatic cancer	7.52e-05	0.000844	CcSEcCtD
Dipyridamole—Paraesthesia—Docetaxel—pancreatic cancer	7.45e-05	0.000836	CcSEcCtD
Dipyridamole—Vomiting—Gemcitabine—pancreatic cancer	7.43e-05	0.000834	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—pancreatic cancer	7.42e-05	0.000833	CcSEcCtD
Dipyridamole—Dyspnoea—Docetaxel—pancreatic cancer	7.39e-05	0.00083	CcSEcCtD
Dipyridamole—Somnolence—Docetaxel—pancreatic cancer	7.37e-05	0.000828	CcSEcCtD
Dipyridamole—Rash—Gemcitabine—pancreatic cancer	7.37e-05	0.000828	CcSEcCtD
Dipyridamole—Dermatitis—Gemcitabine—pancreatic cancer	7.36e-05	0.000827	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—pancreatic cancer	7.34e-05	0.000824	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—pancreatic cancer	7.32e-05	0.000822	CcSEcCtD
Dipyridamole—Headache—Gemcitabine—pancreatic cancer	7.32e-05	0.000822	CcSEcCtD
Dipyridamole—Flushing—Epirubicin—pancreatic cancer	7.31e-05	0.000821	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—pancreatic cancer	7.31e-05	0.000821	CcSEcCtD
Dipyridamole—Vomiting—Fluorouracil—pancreatic cancer	7.31e-05	0.00082	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—pancreatic cancer	7.3e-05	0.00082	CcSEcCtD
Dipyridamole—Dyspepsia—Docetaxel—pancreatic cancer	7.3e-05	0.00082	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—pancreatic cancer	7.29e-05	0.000818	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—pancreatic cancer	7.29e-05	0.000818	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—pancreatic cancer	7.25e-05	0.000814	CcSEcCtD
Dipyridamole—Rash—Fluorouracil—pancreatic cancer	7.25e-05	0.000814	CcSEcCtD
Dipyridamole—Dermatitis—Fluorouracil—pancreatic cancer	7.24e-05	0.000813	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—pancreatic cancer	7.23e-05	0.000812	CcSEcCtD
Dipyridamole—Headache—Fluorouracil—pancreatic cancer	7.2e-05	0.000808	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Docetaxel—pancreatic cancer	7.16e-05	0.000804	CcSEcCtD
Dipyridamole—Fatigue—Docetaxel—pancreatic cancer	7.15e-05	0.000803	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—pancreatic cancer	7.14e-05	0.000802	CcSEcCtD
Dipyridamole—Nausea—Irinotecan—pancreatic cancer	7.13e-05	0.0008	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—pancreatic cancer	7.11e-05	0.000799	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—pancreatic cancer	7.1e-05	0.000797	CcSEcCtD
Dipyridamole—Pain—Docetaxel—pancreatic cancer	7.09e-05	0.000796	CcSEcCtD
Dipyridamole—Chills—Epirubicin—pancreatic cancer	7.07e-05	0.000793	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—pancreatic cancer	7.03e-05	0.00079	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—pancreatic cancer	6.96e-05	0.000781	CcSEcCtD
Dipyridamole—Nausea—Gemcitabine—pancreatic cancer	6.94e-05	0.00078	CcSEcCtD
Dipyridamole—Feeling abnormal—Docetaxel—pancreatic cancer	6.83e-05	0.000768	CcSEcCtD
Dipyridamole—Nausea—Fluorouracil—pancreatic cancer	6.83e-05	0.000767	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—pancreatic cancer	6.79e-05	0.000763	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.78e-05	0.000762	CcSEcCtD
Dipyridamole—Cardiac disorder—Doxorubicin—pancreatic cancer	6.76e-05	0.000759	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—pancreatic cancer	6.76e-05	0.000759	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—pancreatic cancer	6.75e-05	0.000759	CcSEcCtD
Dipyridamole—Tension—Epirubicin—pancreatic cancer	6.73e-05	0.000755	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—pancreatic cancer	6.71e-05	0.000754	CcSEcCtD
Dipyridamole—Nervousness—Epirubicin—pancreatic cancer	6.66e-05	0.000748	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—pancreatic cancer	6.63e-05	0.000745	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—pancreatic cancer	6.61e-05	0.000742	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—pancreatic cancer	6.59e-05	0.00074	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—pancreatic cancer	6.58e-05	0.000739	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—pancreatic cancer	6.57e-05	0.000737	CcSEcCtD
Dipyridamole—Abdominal pain—Docetaxel—pancreatic cancer	6.56e-05	0.000736	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—pancreatic cancer	6.54e-05	0.000734	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—pancreatic cancer	6.51e-05	0.000731	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—pancreatic cancer	6.44e-05	0.000723	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—pancreatic cancer	6.36e-05	0.000714	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—pancreatic cancer	6.34e-05	0.000711	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—pancreatic cancer	6.25e-05	0.000702	CcSEcCtD
Dipyridamole—Tension—Doxorubicin—pancreatic cancer	6.22e-05	0.000699	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—pancreatic cancer	6.21e-05	0.000697	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—pancreatic cancer	6.18e-05	0.000694	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—pancreatic cancer	6.16e-05	0.000692	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—pancreatic cancer	6.16e-05	0.000692	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—pancreatic cancer	6.15e-05	0.00069	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—pancreatic cancer	6.13e-05	0.000689	CcSEcCtD
Dipyridamole—Hypersensitivity—Docetaxel—pancreatic cancer	6.11e-05	0.000686	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—pancreatic cancer	6.1e-05	0.000685	CcSEcCtD
Dipyridamole—Palpitations—Epirubicin—pancreatic cancer	6.06e-05	0.00068	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—pancreatic cancer	6.02e-05	0.000677	CcSEcCtD
Dipyridamole—Cough—Epirubicin—pancreatic cancer	5.98e-05	0.000672	CcSEcCtD
Dipyridamole—PDE8B—islet of Langerhans—pancreatic cancer	5.95e-05	0.131	CbGeAlD
Dipyridamole—Asthenia—Docetaxel—pancreatic cancer	5.95e-05	0.000668	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—pancreatic cancer	5.94e-05	0.000667	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—pancreatic cancer	5.92e-05	0.000665	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.88e-05	0.000661	CcSEcCtD
Dipyridamole—Pruritus—Docetaxel—pancreatic cancer	5.87e-05	0.000659	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—pancreatic cancer	5.86e-05	0.000658	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—pancreatic cancer	5.84e-05	0.000655	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—pancreatic cancer	5.84e-05	0.000655	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—pancreatic cancer	5.84e-05	0.000655	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—pancreatic cancer	5.82e-05	0.000653	CcSEcCtD
Dipyridamole—PDE3B—islet of Langerhans—pancreatic cancer	5.81e-05	0.128	CbGeAlD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	5.8e-05	0.000651	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—pancreatic cancer	5.77e-05	0.000647	CcSEcCtD
Dipyridamole—Malaise—Doxorubicin—pancreatic cancer	5.72e-05	0.000642	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—pancreatic cancer	5.71e-05	0.000641	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—pancreatic cancer	5.7e-05	0.00064	CcSEcCtD
Dipyridamole—Syncope—Doxorubicin—pancreatic cancer	5.69e-05	0.000639	CcSEcCtD
Dipyridamole—Diarrhoea—Docetaxel—pancreatic cancer	5.67e-05	0.000637	CcSEcCtD
Dipyridamole—Palpitations—Doxorubicin—pancreatic cancer	5.6e-05	0.000629	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—pancreatic cancer	5.59e-05	0.000628	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—pancreatic cancer	5.59e-05	0.000628	CcSEcCtD
Dipyridamole—Loss of consciousness—Doxorubicin—pancreatic cancer	5.57e-05	0.000626	CcSEcCtD
Dipyridamole—Cough—Doxorubicin—pancreatic cancer	5.53e-05	0.000622	CcSEcCtD
Dipyridamole—Shock—Epirubicin—pancreatic cancer	5.5e-05	0.000618	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—pancreatic cancer	5.5e-05	0.000617	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—pancreatic cancer	5.49e-05	0.000616	CcSEcCtD
Dipyridamole—Dizziness—Docetaxel—pancreatic cancer	5.48e-05	0.000616	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—pancreatic cancer	5.48e-05	0.000615	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—pancreatic cancer	5.48e-05	0.000615	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—pancreatic cancer	5.46e-05	0.000613	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—pancreatic cancer	5.43e-05	0.00061	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—pancreatic cancer	5.41e-05	0.000607	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—pancreatic cancer	5.4e-05	0.000606	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—pancreatic cancer	5.4e-05	0.000606	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—pancreatic cancer	5.4e-05	0.000606	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—pancreatic cancer	5.38e-05	0.000604	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.36e-05	0.000602	CcSEcCtD
Dipyridamole—PDE8A—islet of Langerhans—pancreatic cancer	5.35e-05	0.118	CbGeAlD
Dipyridamole—Discomfort—Doxorubicin—pancreatic cancer	5.33e-05	0.000599	CcSEcCtD
Dipyridamole—Dry mouth—Doxorubicin—pancreatic cancer	5.28e-05	0.000593	CcSEcCtD
Dipyridamole—Vomiting—Docetaxel—pancreatic cancer	5.27e-05	0.000592	CcSEcCtD
Dipyridamole—Rash—Docetaxel—pancreatic cancer	5.23e-05	0.000587	CcSEcCtD
Dipyridamole—Hypotension—Epirubicin—pancreatic cancer	5.23e-05	0.000587	CcSEcCtD
Dipyridamole—Dermatitis—Docetaxel—pancreatic cancer	5.22e-05	0.000587	CcSEcCtD
Dipyridamole—Headache—Docetaxel—pancreatic cancer	5.2e-05	0.000583	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—pancreatic cancer	5.18e-05	0.000581	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—pancreatic cancer	5.18e-05	0.000581	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.1e-05	0.000572	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—pancreatic cancer	5.09e-05	0.000572	CcSEcCtD
Dipyridamole—Nervous system disorder—Doxorubicin—pancreatic cancer	5.08e-05	0.00057	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.07e-05	0.000569	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—pancreatic cancer	5.05e-05	0.000567	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—pancreatic cancer	5.03e-05	0.000565	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—pancreatic cancer	5.02e-05	0.000564	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—pancreatic cancer	5e-05	0.000562	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—pancreatic cancer	4.99e-05	0.00056	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—pancreatic cancer	4.97e-05	0.000558	CcSEcCtD
Dipyridamole—Nausea—Docetaxel—pancreatic cancer	4.93e-05	0.000553	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—pancreatic cancer	4.92e-05	0.000553	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—pancreatic cancer	4.84e-05	0.000543	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.83e-05	0.000542	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—pancreatic cancer	4.82e-05	0.000542	CcSEcCtD
Dipyridamole—Pain—Epirubicin—pancreatic cancer	4.78e-05	0.000537	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.72e-05	0.00053	CcSEcCtD
Dipyridamole—Paraesthesia—Doxorubicin—pancreatic cancer	4.65e-05	0.000522	CcSEcCtD
Dipyridamole—Dyspnoea—Doxorubicin—pancreatic cancer	4.61e-05	0.000518	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—pancreatic cancer	4.61e-05	0.000518	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—pancreatic cancer	4.6e-05	0.000517	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.57e-05	0.000514	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—pancreatic cancer	4.56e-05	0.000512	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.47e-05	0.000502	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—pancreatic cancer	4.46e-05	0.000501	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—pancreatic cancer	4.44e-05	0.000499	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—pancreatic cancer	4.43e-05	0.000497	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—pancreatic cancer	4.42e-05	0.000497	CcSEcCtD
Dipyridamole—Feeling abnormal—Doxorubicin—pancreatic cancer	4.27e-05	0.000479	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.23e-05	0.000475	CcSEcCtD
Dipyridamole—Hypersensitivity—Epirubicin—pancreatic cancer	4.12e-05	0.000463	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—pancreatic cancer	4.11e-05	0.000462	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—pancreatic cancer	4.09e-05	0.00046	CcSEcCtD
Dipyridamole—PDE3B—pancreas—pancreatic cancer	4.09e-05	0.0898	CbGeAlD
Dipyridamole—Asthenia—Epirubicin—pancreatic cancer	4.01e-05	0.000451	CcSEcCtD
Dipyridamole—Pruritus—Epirubicin—pancreatic cancer	3.96e-05	0.000444	CcSEcCtD
Dipyridamole—Diarrhoea—Epirubicin—pancreatic cancer	3.83e-05	0.00043	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—pancreatic cancer	3.81e-05	0.000428	CcSEcCtD
Dipyridamole—PDE8A—pancreas—pancreatic cancer	3.76e-05	0.0827	CbGeAlD
Dipyridamole—PDE10A—digestive system—pancreatic cancer	3.75e-05	0.0824	CbGeAlD
Dipyridamole—Asthenia—Doxorubicin—pancreatic cancer	3.71e-05	0.000417	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—pancreatic cancer	3.7e-05	0.000415	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—pancreatic cancer	3.66e-05	0.000411	CcSEcCtD
Dipyridamole—Vomiting—Epirubicin—pancreatic cancer	3.56e-05	0.000399	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—pancreatic cancer	3.54e-05	0.000398	CcSEcCtD
Dipyridamole—Rash—Epirubicin—pancreatic cancer	3.53e-05	0.000396	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—pancreatic cancer	3.52e-05	0.000396	CcSEcCtD
Dipyridamole—Headache—Epirubicin—pancreatic cancer	3.5e-05	0.000394	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—pancreatic cancer	3.42e-05	0.000384	CcSEcCtD
Dipyridamole—Nausea—Epirubicin—pancreatic cancer	3.32e-05	0.000373	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—pancreatic cancer	3.29e-05	0.00037	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—pancreatic cancer	3.26e-05	0.000367	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—pancreatic cancer	3.26e-05	0.000366	CcSEcCtD
Dipyridamole—Headache—Doxorubicin—pancreatic cancer	3.24e-05	0.000364	CcSEcCtD
Dipyridamole—Nausea—Doxorubicin—pancreatic cancer	3.07e-05	0.000345	CcSEcCtD
Dipyridamole—SLC29A1—islet of Langerhans—pancreatic cancer	3.07e-05	0.0674	CbGeAlD
Dipyridamole—ADA—digestive system—pancreatic cancer	2.64e-05	0.0582	CbGeAlD
Dipyridamole—PDE5A—digestive system—pancreatic cancer	2.19e-05	0.0482	CbGeAlD
Dipyridamole—SLC29A1—pancreas—pancreatic cancer	2.15e-05	0.0474	CbGeAlD
Dipyridamole—SLC29A1—digestive system—pancreatic cancer	1.84e-05	0.0405	CbGeAlD
Dipyridamole—ABCC4—pancreas—pancreatic cancer	1.63e-05	0.0358	CbGeAlD
Dipyridamole—ABCC4—digestive system—pancreatic cancer	1.39e-05	0.0305	CbGeAlD
Dipyridamole—ABCB1—islet of Langerhans—pancreatic cancer	8.05e-06	0.0177	CbGeAlD
Dipyridamole—ABCB1—pancreas—pancreatic cancer	5.66e-06	0.0125	CbGeAlD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	5.22e-06	4.87e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—EGFR—pancreatic cancer	5.21e-06	4.87e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CD—pancreatic cancer	5.17e-06	4.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CTNNB1—pancreatic cancer	5.17e-06	4.83e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—PIK3CA—pancreatic cancer	5.13e-06	4.8e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—KRAS—pancreatic cancer	5.13e-06	4.79e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.12e-06	4.78e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	5.11e-06	4.78e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—SRC—pancreatic cancer	5.11e-06	4.77e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—PIK3CA—pancreatic cancer	5.09e-06	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—PIK3CA—pancreatic cancer	5.09e-06	4.75e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTEN—pancreatic cancer	5.08e-06	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTEN—pancreatic cancer	5.08e-06	4.75e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NFKBIA—pancreatic cancer	5.08e-06	4.74e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—KRAS—pancreatic cancer	5.06e-06	4.73e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—HRAS—pancreatic cancer	5.06e-06	4.73e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—KRAS—pancreatic cancer	5.06e-06	4.73e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PTEN—pancreatic cancer	5.04e-06	4.7e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NOTCH1—pancreatic cancer	5.03e-06	4.7e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CD—pancreatic cancer	5.03e-06	4.7e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—AKT1—pancreatic cancer	5.01e-06	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—AKT1—pancreatic cancer	5.01e-06	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—AKT1—pancreatic cancer	4.98e-06	4.66e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.98e-06	4.65e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—TP53—pancreatic cancer	4.97e-06	4.64e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—PIK3CA—pancreatic cancer	4.96e-06	4.64e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—KRAS—pancreatic cancer	4.93e-06	4.61e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CB—pancreatic cancer	4.93e-06	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—STAT3—pancreatic cancer	4.92e-06	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—KRAS—pancreatic cancer	4.92e-06	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TP53—pancreatic cancer	4.92e-06	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TP53—pancreatic cancer	4.92e-06	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CG—pancreatic cancer	4.92e-06	4.59e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—NRAS—pancreatic cancer	4.92e-06	4.59e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—NRAS—pancreatic cancer	4.91e-06	4.59e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—EGFR—pancreatic cancer	4.9e-06	4.58e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—AKT1—pancreatic cancer	4.89e-06	4.56e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTGS2—pancreatic cancer	4.88e-06	4.56e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	4.87e-06	4.55e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGF—pancreatic cancer	4.86e-06	4.54e-05	CbGpPWpGaD
Dipyridamole—ABCB1—digestive system—pancreatic cancer	4.84e-06	0.0106	CbGeAlD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	4.83e-06	4.51e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CB—pancreatic cancer	4.81e-06	4.49e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CTNNB1—pancreatic cancer	4.77e-06	4.46e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—HRAS—pancreatic cancer	4.75e-06	4.44e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CD—pancreatic cancer	4.73e-06	4.42e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—SRC—pancreatic cancer	4.71e-06	4.4e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—SRC—pancreatic cancer	4.71e-06	4.4e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—PIK3CA—pancreatic cancer	4.71e-06	4.4e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HRAS—pancreatic cancer	4.7e-06	4.4e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HRAS—pancreatic cancer	4.7e-06	4.4e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.68e-06	4.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—SRC—pancreatic cancer	4.67e-06	4.36e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—PIK3CA—pancreatic cancer	4.65e-06	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTEN—pancreatic cancer	4.65e-06	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.65e-06	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—KRAS—pancreatic cancer	4.63e-06	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CXCL8—pancreatic cancer	4.62e-06	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—HRAS—pancreatic cancer	4.59e-06	4.29e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—pancreatic cancer	4.56e-06	4.26e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—STAT3—pancreatic cancer	4.55e-06	4.25e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—STAT3—pancreatic cancer	4.55e-06	4.25e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NRAS—pancreatic cancer	4.54e-06	4.24e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NRAS—pancreatic cancer	4.54e-06	4.24e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PIK3CA—pancreatic cancer	4.53e-06	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.52e-06	4.22e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CB—pancreatic cancer	4.5e-06	4.21e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—STAT3—pancreatic cancer	4.5e-06	4.21e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—pancreatic cancer	4.5e-06	4.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—NRAS—pancreatic cancer	4.49e-06	4.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EGFR—pancreatic cancer	4.48e-06	4.19e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EGFR—pancreatic cancer	4.48e-06	4.18e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—pancreatic cancer	4.47e-06	4.17e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—pancreatic cancer	4.47e-06	4.17e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	4.44e-06	4.15e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CASP3—pancreatic cancer	4.43e-06	4.13e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—pancreatic cancer	4.38e-06	4.1e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CB—pancreatic cancer	4.38e-06	4.09e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—pancreatic cancer	4.36e-06	4.07e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CXCL8—pancreatic cancer	4.33e-06	4.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CD—pancreatic cancer	4.32e-06	4.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—SRC—pancreatic cancer	4.31e-06	4.03e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—pancreatic cancer	4.31e-06	4.02e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—pancreatic cancer	4.3e-06	4.02e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—pancreatic cancer	4.3e-06	4.02e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GLP1R—pancreatic cancer	4.29e-06	4.01e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	4.29e-06	4.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.28e-06	4e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CTNNB1—pancreatic cancer	4.27e-06	3.98e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTEN—pancreatic cancer	4.26e-06	3.98e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.25e-06	3.97e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—pancreatic cancer	4.23e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—pancreatic cancer	4.23e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—DPYD—pancreatic cancer	4.23e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—pancreatic cancer	4.22e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—pancreatic cancer	4.22e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TGFB1—pancreatic cancer	4.21e-06	3.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TGFB1—pancreatic cancer	4.21e-06	3.94e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CXCL8—pancreatic cancer	4.21e-06	3.93e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—pancreatic cancer	4.19e-06	3.92e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—pancreatic cancer	4.19e-06	3.92e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—pancreatic cancer	4.18e-06	3.91e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—pancreatic cancer	4.18e-06	3.91e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—pancreatic cancer	4.18e-06	3.91e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—STAT3—pancreatic cancer	4.16e-06	3.88e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PTEN—pancreatic cancer	4.16e-06	3.88e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—pancreatic cancer	4.15e-06	3.88e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—pancreatic cancer	4.15e-06	3.88e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NRAS—pancreatic cancer	4.15e-06	3.88e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CASP3—pancreatic cancer	4.14e-06	3.87e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PIK3CA—pancreatic cancer	4.13e-06	3.86e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EGFR—pancreatic cancer	4.13e-06	3.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EGFR—pancreatic cancer	4.13e-06	3.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CB—pancreatic cancer	4.12e-06	3.85e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EGFR—pancreatic cancer	4.09e-06	3.82e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—pancreatic cancer	4.07e-06	3.8e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—pancreatic cancer	4.06e-06	3.79e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—pancreatic cancer	4.03e-06	3.77e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CASP3—pancreatic cancer	4.03e-06	3.77e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC2A2—pancreatic cancer	4.01e-06	3.75e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CTNNB1—pancreatic cancer	3.99e-06	3.73e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CXCL8—pancreatic cancer	3.96e-06	3.7e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—pancreatic cancer	3.93e-06	3.67e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—pancreatic cancer	3.92e-06	3.66e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—pancreatic cancer	3.92e-06	3.66e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—pancreatic cancer	3.9e-06	3.65e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—pancreatic cancer	3.9e-06	3.65e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PTEN—pancreatic cancer	3.89e-06	3.64e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—PIK3CA—pancreatic cancer	3.89e-06	3.63e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CTNNB1—pancreatic cancer	3.88e-06	3.63e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PIK3CA—pancreatic cancer	3.88e-06	3.63e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—pancreatic cancer	3.87e-06	3.61e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—pancreatic cancer	3.86e-06	3.61e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—SRC—pancreatic cancer	3.86e-06	3.6e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—TGFB1—pancreatic cancer	3.85e-06	3.6e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—pancreatic cancer	3.85e-06	3.6e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—pancreatic cancer	3.82e-06	3.57e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—pancreatic cancer	3.81e-06	3.56e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—pancreatic cancer	3.8e-06	3.55e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—pancreatic cancer	3.8e-06	3.55e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CASP3—pancreatic cancer	3.79e-06	3.54e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PTEN—pancreatic cancer	3.79e-06	3.54e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EGFR—pancreatic cancer	3.78e-06	3.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CB—pancreatic cancer	3.77e-06	3.52e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—pancreatic cancer	3.75e-06	3.51e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STAT3—pancreatic cancer	3.72e-06	3.47e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NRAS—pancreatic cancer	3.71e-06	3.46e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—pancreatic cancer	3.7e-06	3.46e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—pancreatic cancer	3.69e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—pancreatic cancer	3.69e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CTNNB1—pancreatic cancer	3.65e-06	3.41e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.63e-06	3.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CXCL8—pancreatic cancer	3.62e-06	3.38e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—SRC—pancreatic cancer	3.61e-06	3.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—pancreatic cancer	3.6e-06	3.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—pancreatic cancer	3.59e-06	3.36e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PIK3CA—pancreatic cancer	3.59e-06	3.35e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PIK3CA—pancreatic cancer	3.59e-06	3.35e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—pancreatic cancer	3.58e-06	3.35e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—pancreatic cancer	3.57e-06	3.34e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTEN—pancreatic cancer	3.56e-06	3.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PIK3CA—pancreatic cancer	3.55e-06	3.32e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—pancreatic cancer	3.52e-06	3.28e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—SRC—pancreatic cancer	3.51e-06	3.28e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—pancreatic cancer	3.5e-06	3.27e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STAT3—pancreatic cancer	3.48e-06	3.25e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—pancreatic cancer	3.47e-06	3.24e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRAS—pancreatic cancer	3.47e-06	3.24e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CASP3—pancreatic cancer	3.47e-06	3.24e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—pancreatic cancer	3.45e-06	3.23e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TGFB1—pancreatic cancer	3.45e-06	3.22e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—pancreatic cancer	3.42e-06	3.2e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STAT3—pancreatic cancer	3.39e-06	3.16e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EGFR—pancreatic cancer	3.38e-06	3.16e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRAS—pancreatic cancer	3.38e-06	3.16e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—pancreatic cancer	3.38e-06	3.15e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—pancreatic cancer	3.37e-06	3.15e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CTNNB1—pancreatic cancer	3.34e-06	3.12e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—pancreatic cancer	3.32e-06	3.1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—pancreatic cancer	3.32e-06	3.1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SRC—pancreatic cancer	3.3e-06	3.08e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—pancreatic cancer	3.29e-06	3.07e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PIK3CA—pancreatic cancer	3.28e-06	3.06e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—pancreatic cancer	3.28e-06	3.06e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTEN—pancreatic cancer	3.26e-06	3.04e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—pancreatic cancer	3.23e-06	3.02e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TGFB1—pancreatic cancer	3.23e-06	3.01e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—pancreatic cancer	3.22e-06	3e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—pancreatic cancer	3.19e-06	2.98e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STAT3—pancreatic cancer	3.18e-06	2.97e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—pancreatic cancer	3.18e-06	2.97e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRAS—pancreatic cancer	3.18e-06	2.97e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—pancreatic cancer	3.17e-06	2.96e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EGFR—pancreatic cancer	3.16e-06	2.96e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—pancreatic cancer	3.15e-06	2.94e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TGFB1—pancreatic cancer	3.14e-06	2.93e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CD44—pancreatic cancer	3.1e-06	2.9e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EGFR—pancreatic cancer	3.08e-06	2.88e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—pancreatic cancer	3.03e-06	2.84e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SRC—pancreatic cancer	3.02e-06	2.82e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CA—pancreatic cancer	3e-06	2.81e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—pancreatic cancer	2.99e-06	2.79e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GCG—pancreatic cancer	2.98e-06	2.78e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—pancreatic cancer	2.96e-06	2.76e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TGFB1—pancreatic cancer	2.95e-06	2.76e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—pancreatic cancer	2.94e-06	2.75e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CA—pancreatic cancer	2.93e-06	2.74e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—pancreatic cancer	2.93e-06	2.74e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—pancreatic cancer	2.93e-06	2.74e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STAT3—pancreatic cancer	2.91e-06	2.72e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—pancreatic cancer	2.91e-06	2.72e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRAS—pancreatic cancer	2.9e-06	2.71e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—pancreatic cancer	2.9e-06	2.71e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EGFR—pancreatic cancer	2.89e-06	2.7e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—pancreatic cancer	2.84e-06	2.65e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—STK11—pancreatic cancer	2.8e-06	2.61e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CA—pancreatic cancer	2.75e-06	2.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—pancreatic cancer	2.73e-06	2.55e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—pancreatic cancer	2.71e-06	2.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—pancreatic cancer	2.71e-06	2.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TGFB1—pancreatic cancer	2.7e-06	2.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—pancreatic cancer	2.68e-06	2.5e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CA—pancreatic cancer	2.67e-06	2.5e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—pancreatic cancer	2.66e-06	2.48e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGFR—pancreatic cancer	2.65e-06	2.47e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—pancreatic cancer	2.58e-06	2.41e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—pancreatic cancer	2.54e-06	2.37e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.51e-06	2.35e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—pancreatic cancer	2.5e-06	2.34e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—pancreatic cancer	2.47e-06	2.31e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—pancreatic cancer	2.45e-06	2.29e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—pancreatic cancer	2.43e-06	2.27e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TYMS—pancreatic cancer	2.41e-06	2.25e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—pancreatic cancer	2.4e-06	2.24e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—pancreatic cancer	2.32e-06	2.17e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CA—pancreatic cancer	2.3e-06	2.15e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—pancreatic cancer	2.24e-06	2.1e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—pancreatic cancer	2.22e-06	2.08e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—pancreatic cancer	2.18e-06	2.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—pancreatic cancer	2.13e-06	1.99e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—pancreatic cancer	2.05e-06	1.92e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOE—pancreatic cancer	1.96e-06	1.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—pancreatic cancer	1.88e-06	1.75e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.77e-06	1.65e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—pancreatic cancer	1.71e-06	1.59e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.55e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.35e-06	1.26e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.34e-06	1.25e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTEN—pancreatic cancer	1.17e-06	1.09e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CA—pancreatic cancer	8.25e-07	7.71e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—pancreatic cancer	6.74e-07	6.3e-06	CbGpPWpGaD
